A multicentric, prospective, observational study evaluating the use patterns of Sebium night peel for acne-prone skin and associated conditions

Aseem Sharma, M. Gautam, K. Godse, Richa Sharma, Padmavathi Surapaneni, M. Agrawal
{"title":"A multicentric, prospective, observational study evaluating the use patterns of Sebium night peel for acne-prone skin and associated conditions","authors":"Aseem Sharma, M. Gautam, K. Godse, Richa Sharma, Padmavathi Surapaneni, M. Agrawal","doi":"10.18203/issn.2455-4529.intjresdermatol20232537","DOIUrl":null,"url":null,"abstract":"Background: Acne is a common skin disorder that affects both adolescents and adults and is categorized as an inflammatory dermatosis. Persistent adult acne is prevalent in more than 80% of cases. Chemical peels are widely used in acne therapy due to their various benefits, including exfoliation, acne lesion reduction, complexion radiance improvement, and scar repair. The procedure, consisting of 2 to 8 sessions, is ideal for adult women with oily skin, acne breakouts, and concerns about photoaging and complexion radiance.\nMethods: A cohort of Indian dermatologists were provided a questionnaire related to the quantum of weekly acne patients seen and their clinical expertise regarding the use of Sebium Night Peel containing 15% glycolic acid, the Fluidactiv™ patented complex & D-panthenol. These results were later analyzed using a standardised visual analogue scale.\nResults: The study enrolled 826 patients, and complete responses were received from 73 dermatologists practicing clinical and aesthetic dermatology across major cities in India. The study revealed that 97% of dermatologists would recommend the Sebium Night Peel as a chemical peel for patients with acne and acne-related complications. The majority of dermatologists rated the peel's tolerability and safety as \"good\" across various evaluation criteria. Additionally, 97% of dermatologists reported no safety concerns associated with the Sebium Night Peel.\nConclusions: This study establishes the Sebium Night Peel as a preferred and effective chemical peel for managing acne-prone skin and associated conditions, as endorsed by dermatologists across India.","PeriodicalId":14331,"journal":{"name":"International Journal of Research in Dermatology","volume":"54 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2455-4529.intjresdermatol20232537","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Acne is a common skin disorder that affects both adolescents and adults and is categorized as an inflammatory dermatosis. Persistent adult acne is prevalent in more than 80% of cases. Chemical peels are widely used in acne therapy due to their various benefits, including exfoliation, acne lesion reduction, complexion radiance improvement, and scar repair. The procedure, consisting of 2 to 8 sessions, is ideal for adult women with oily skin, acne breakouts, and concerns about photoaging and complexion radiance. Methods: A cohort of Indian dermatologists were provided a questionnaire related to the quantum of weekly acne patients seen and their clinical expertise regarding the use of Sebium Night Peel containing 15% glycolic acid, the Fluidactiv™ patented complex & D-panthenol. These results were later analyzed using a standardised visual analogue scale. Results: The study enrolled 826 patients, and complete responses were received from 73 dermatologists practicing clinical and aesthetic dermatology across major cities in India. The study revealed that 97% of dermatologists would recommend the Sebium Night Peel as a chemical peel for patients with acne and acne-related complications. The majority of dermatologists rated the peel's tolerability and safety as "good" across various evaluation criteria. Additionally, 97% of dermatologists reported no safety concerns associated with the Sebium Night Peel. Conclusions: This study establishes the Sebium Night Peel as a preferred and effective chemical peel for managing acne-prone skin and associated conditions, as endorsed by dermatologists across India.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项多中心、前瞻性、观察性研究,评估Sebium夜皮对痤疮易发皮肤和相关状况的使用模式
背景:痤疮是一种常见的皮肤疾病,影响青少年和成人,被归类为炎症性皮肤病。持续的成人痤疮在80%以上的病例中普遍存在。化学换肤术被广泛应用于痤疮治疗,因为它有多种好处,包括去角质,减少痤疮病变,改善肤色,修复疤痕。这个过程包括2到8个疗程,对于油性皮肤、痤疮爆发、担心光老化和肤色光泽的成年女性来说是理想的。方法:研究人员向一组印度皮肤科医生提供了一份问卷,问卷内容涉及每周见到的痤疮患者数量,以及他们使用含有15%乙醇酸、Fluidactiv™专利复合物和d -泛醇的Sebium夜皮的临床专业知识。这些结果随后使用标准化视觉模拟量表进行分析。结果:该研究招募了826名患者,并从印度主要城市的73名皮肤科医生那里收到了完整的回复。研究显示,97%的皮肤科医生会推荐Sebium夜皮作为化学去皮,用于痤疮和痤疮相关并发症的患者。大多数皮肤科医生在各种评估标准中将果皮的耐受性和安全性评为“良好”。此外,97%的皮肤科医生报告没有与Sebium夜皮相关的安全问题。结论:这项研究确立了Sebium夜皮作为一种首选和有效的化学剥皮,用于管理痤疮易发皮肤和相关条件,得到了印度皮肤科医生的认可。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Dupilumab as a treatment for a case of benign familial pemphigus A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin Tofaticinib as a potential therapeutic agent: a review The evaluation of serum vitamin D3 in androgenetic alopecia: a case-control study Aleukemic leukemia cutis: a rare case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1